ESC 365 - Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial

HFA Premium Access

Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial

Session: Poster Session 1 - Metabolism - Diabetes mellitus - Obesity

Topic: Metabolism / Diabetes mellitus

Speaker: Doctor D. Fitchett (Toronto, CA)

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

18 presentations

0 follower

8 more presentations in this session

Relationship between cardiac autonomic neuropathy and heart rate variability in young patients with type 1 diabetes mellitus

The relationship between glycemic control and preclinical diastolic dysfunction in patients with type 2 diabetes mellitus or prediabetes

Speaker: Doctor A. Banushi (Tirana, AL)

Weight gain was associated with better prognosis after hospital discharge in patients admitted with heart failure

Speaker: Doctor R. Agra Bermejo (Santiago de Compostela, ES)

Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients

Speaker: Professor K. Koh (Incheon, KR)

Significance of speckle-tracking in identifying subclinical myocardial injury of young patients with Type1 Diabetes mellitus without cardiovascular disease.

Access the full session

Poster Session 1 - Metabolism - Diabetes mellitus - Obesity

Speakers: Doctor D. Fitchett, Doctor A. Banushi, Doctor R. Agra Bermejo, Professor K. Koh

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources